A PHASE II, MULTICENTRE, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF ZD1839 (IRESSA?) IN COMBINATION WITH CASODEX? IN PATIENTS WITH OPERABLE PROSTATE CANCER

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-000495-14-IT

Enrollment

Unknown

Registered

2004-12-14

Start date

2005-03-14

Completion date

Unknown

Last updated

2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

OPERABLE PROSTATE CANCER MedDRA version: 6.1 Level: PT Classification code 10060862

Interventions

Trade Name: L01XX31 - Gefitinib Product Name: Gefitinib Product Code: ZD 1839 Pharmaceutical Form: Tablet INN or Proposed INN: Gefitinib Current Sponsor code: D7913L00031 Concentration unit: mg milli

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026